2020 China orthopaedic implantable medical device industry and market segment development scale and trend forecast.

Medicine Network October 15 - Thanks to China's huge population base, the accelerated process of social aging and rising medical demand, China's orthopaedic implantable medical device market sales revenue increased from 16.4 billion yuan in 2015 to 30.8 billion yuan in 2019, a compound growth rate of 17.03 percent.
expected that by 2020, the national market size of orthopaedic implantable medical devices will reach 36 billion yuan.
in terms of composition, unlike joint products, which account for the largest market share in the global orthopaedic implantable device market, the largest category in China's orthopaedic implantable medical device market is trauma, with a market share of 29.80% in 2019.
market characteristics are mainly caused by the un-developed maturity of China's orthopaedic implant market.
with the improvement of china's residents' consumption capacity and the acceptance of high-end orthopaedic implants, China's spine and joint market share will continue to increase.
data sources: Guangzhou Punctuation Pharmaceutical Information Co., Ltd., China Commercial Industry Research Institute finishing (i) trauma implant devices, refers to the treatment of limbs and other types of fracture damage implants, can play reset, fixation and other functions, including myelin nails, bone plates and screws.
2015-2019, sales revenue in the trauma implants market increased from 5.1 billion yuan to 9.2 billion yuan, with a compound growth rate of 15.76 percent, according to the Company.
the market development of trauma-related products is more adequate, is China's orthopaedic implantable medical device market's largest segment category.
expected that by 2020, the size of the national trauma implant market is expected to exceed 10 billion yuan.
(ii) Spinal implantable consumables spinal implants, refers to surgical treatment implants used to treat diseases such as spinal malformation, scoliosis, degenerative lumbar disc lesions, degenerative thoracic lumbar stooping, vertebral slip, spinal spinal instability in the thoracic lumbar section, spinal tumors, etc.
spine is a human central axis bone that supports the torso and protects the nerves and internal organs of the spinal cord.
the spine, known as the "second lifeline of the human body", can pose a serious threat to people's health due to degeneration, fractures, congenital and idexual causes.
, there is a wide range of implantable spinal orthopaedic devices on the market, including thoracic lumbar nail plate systems, cervical nail plate systems and fusion device systems.
cervical nail plate system is suitable for the treatment of pathological diseases such as cervical de-defying diseases, trauma and tumors.
thoracic lumbar nail plate system is mainly used to treat severe mechanical instability or malformation of the thoracic lumbar vertebrae and timurs that need to be fused by instruments, as well as thoracic lumbar fractures and disalsosis.
fusion system is mainly used for the treatment of disc replacement and is the most important segment, accounting for about half of the entire market for spinal implants.
fusion surgery is to partially remove the disc that compresses the nerve for therapeutic purposes.
but removing the disc part of the spine causes the patient's self-bone fusion, affecting the ability to function, and can help restore spinal function by implanting the intervertebral fusion system.
2015-2019, sales revenue in the spinal implant market increased from 4.7 billion yuan to 8.7 billion yuan, with a compound growth rate of 16.58 percent, according to the company.
china's spinal implant market is expected to reach 10 billion yuan by 2020.
(iii) vertebral forming surgical system percutaneous vertebral forming (Percutaneous Vertebroplasty, PVP) and percutaneous balloon dilation vertebral protrusion (Percutaneous Kyphoplasty, PKP) are more Mature neurodegenerative OVCF (osteoporosis vertebral compression fracture) minimally invasive surgical methods, both have the same therapeutic adaptation, including osteoporosis vertebral compression fracture, vertebral hemangioma, myeloma and other primary malignancies, of which OVCF is the most widely used.
According to the Guidelines for the Treatment of Compression Fractures of Osteoporosis Vertebrals, for OVCF, although no studies have shown that vertebral forming is superior to conservative treatment, early minimally invasive surgical treatment is the best method of OVCF treatment through clinical experience.
Because fracture surgery is usually performed using traditional open surgery, damage to muscles and ligaments will affect the patient's postoperative rehabilitation, so in recent years the industry in the development of minimally invasive surgery, minimally invasive surgery in the field of the spine more applications, including in-spinal fixed minimally invasive surgery, vertebral forming minimally invasive surgery.
vertebral forming surgery has been used in the world for decades, the technology is mature, in our country is in a rapid growth.
2015-2019, China's market sales revenue of vertebral forming surgical system was 1.4 billion yuan, with a compound growth rate of 16.87 percent and good growth.
2020, China's vertebral forming surgical system sales revenue of about 1.6 billion yuan.
Industry Development Opportunities Analysis In December 2019, the State Health Insurance Administration issued the first batch of unified coding list of medical supplies, a total of 30,332 consumables, of which the largest number of orthopaedic materials, up to 18,537.
application of the unique identification system for medical devices not only lays the foundation for the rule-making of medical insurance access and the negotiation of the price of medical insurance access, but also lays the foundation for the comprehensive volume procurement of medical supplies.
from the release of policies and provincial supplies pilot situation, orthopaedic devices are the focus of medical device industry reform categories, it is expected that the development of orthopaedic implantable medical devices market will be increasingly standardized.
same time, with the "two-vote system" of consumables, from 2019, orthopaedic implantable medical device manufacturers gradually change the way insulation, business revenue will show a higher growth rate than product sales.
, however, based on the "two-vote system" between the provinces of the implementation time and scope of implementation is different, as well as the promotion of import substitution, China's orthopaedic implantable medical device market as a whole sales revenue will not show a significant increase in the trend.
(1) The prevalence of osteoporosis in China's 40-49-year-old population is 3.2%, of which 2.2% are men and 4.3% are women, and the prevalence of osteoporosis among people over 65 years of age is as high as 32.0%, of which 10.7% are men and 51.6% are women.
osteoporosis can cause pain, spinal deformation, fractures, etc.
addition, the elderly mobility is easy to fall, fall injuries, etc. , once the bone tissue injury, more need for treatment and even orthopaedic repair surgery.
china's aging is becoming more and more serious, the demand for orthopaedic products continues to rise.
(2) Lifestyle changes in residents, continued increased activity and frequent travel around the country, the number of traffic accident injuries continued to rise (from 210,000 in 2014 to 260,000 in 2018), car accidents often lead to fractures and other hard tissue damage, the potential demand for orthopaedic products is on the rise.
(3) The country's economic development is fast, the government has increased medical expenditure, the level of medical security has been widened and deepened, reducing the medical burden of the residents.
, residents' demands for quality of life have increased, and the willingness to visit and treatment rates have increased.
From the number of orthopaedic hospital admissions and the number of surgical patients, the number of orthopaedic hospital admissions in China increased from 530,000 to 1.44 million in 2010-2018, and the number of inpatients in orthopaedic hospitals increased from 410,000 to 630,000.
(4) In 2018, the total number of people in our health system reached 12.31 million, the number of doctors per thousand people reached 2.59, the number of nurses per thousand population reached 2.94, exceeding the average in middle-income countries, and the access to health care has greatly improved.
In terms of the supply of orthopaedic surgeons, the number of medical practitioners (including practising assistant physicians) in orthopaedic hospitals in China increased from 8,241 to 15,848 in 2010-2018, supporting the increase in orthopaedic surgery.
(5) In recent years, the state has introduced a number of industrial policies to encourage the innovation of implantable interventional devices, and created a favorable policy environment for domestic products to achieve import substitution.
by virtue of price advantage and policy support, domestic orthopaedic implantable medical devices will gradually realize import substitution from the low-end market to the middle and high-end market.
can effectively reduce the cost of using products, reduce the burden on patients, release potential demand, and promote market development.
(6) Currently, implantable products such as orthopaedic products are shifting from standardized to customized production for more accurate personalized treatment purposes, resulting in a better treatment experience for patients.
In July 2019, the Drug Administration, in cooperation with the Health and Safety Commission, issued the Regulations on the Supervision and Administration of Customized Medical Devices (Trial), effective January 1, 2020, and in October 2019, the Drug Administration issued the Guidelines for the Technical Review of the Registration of Personalized Added Medical Devices for Passive Implanted Bone, Joint and Oral Hard Tissues, which will promote the innovation and development of customized orthopaedic products.
.